Human MxA protein suppresses mammalian H5N1 virus replication, but emerging mutations may enable partial evasion, raising ...

AKS-452 is under clinical development by Vakston and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Pocenbrodib hydrochloride is under clinical development by Pathos AI and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Learn about Nurix Therapeutics (NRIX) focusing on protein degradation in cancer treatment, with promising early-stage data ...

Novel antibodies have the potential to pave the way for the next generation of malaria interventions. Researchers at the ...